These results collectively support the notion of a role of mitochondria reprogramming in sorafenib-resistance and pointed to STAT3 as a relevant player and actionable target, offering new options for the treatment of advanced HCC. The gene discussed is STAT3; the disease is hepatocellular carcinoma.